Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2014 Mar 11;43(3):257–258. doi: 10.3109/03009742.2013.869617

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Taylor & Francis on license from Scandinavian Rheumatology Research Foundation

This is an open-access article distributed under the terms of the CC-BY-NC-ND 3.0 License which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is credited.

PMC Copyright notice

Figure 1. — Changes in (A) the modified Rodnan skin score (mRSS), (B) the diffusing capacity of the lung for carbon monoxide (DLCO), and (C) forced vital capacity (FVC) measurements in all five scleroderma patients (SP, BM, EB, BC, and ZS) treated with rituximab at 0, 3, 6, and 12 months. Changes in mRSS and DLCO are shown as percentages for up to 12 months of treatment with rituximab. There was a significant decrease (mean ± SD) in mRSS in all five patients (26.5 ± 8.3% vs. 11.8 ± 2.9%, p < 0.001). DLCO improved after the therapy with rituximab in all patients (48.5 ± 6.7% vs. 66.0 ± 4.0%, p < 0.001). FVC improved significantly after 6 months (72 ± 5.2% vs. 82 ± 5.9%, p < 0.008) and 12 months (72 ± 5.2% vs. 89 ± 3.2%, p < 0.004).